Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $62.67 and last traded at $60.98, with a volume of 75000 shares trading hands. The stock had previously closed at $60.27.

A number of research firms recently issued reports on ENTA. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Royal Bank of Canada downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a research report on Tuesday, January 2nd. JMP Securities boosted their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Finally, TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $45.25.

The company has a market capitalization of $1,166.30, a PE ratio of 71.32 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The company had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same quarter in the previous year, the firm earned ($0.09) EPS. The firm’s revenue was up 491.3% on a year-over-year basis. equities analysts forecast that Enanta Pharmaceuticals Inc will post -1.57 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can raised its holdings in Enanta Pharmaceuticals by 12.2% during the fourth quarter. Bank of Montreal Can now owns 39,562 shares of the biotechnology company’s stock worth $2,322,000 after buying an additional 4,306 shares during the last quarter. GSA Capital Partners LLP raised its holdings in Enanta Pharmaceuticals by 143.2% during the third quarter. GSA Capital Partners LLP now owns 19,700 shares of the biotechnology company’s stock worth $922,000 after buying an additional 11,600 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Enanta Pharmaceuticals by 1.4% during the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after buying an additional 7,617 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Enanta Pharmaceuticals by 5.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 56,419 shares of the biotechnology company’s stock worth $2,641,000 after buying an additional 2,803 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Enanta Pharmaceuticals during the third quarter worth $220,000. Hedge funds and other institutional investors own 66.83% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Enanta Pharmaceuticals (ENTA) Hits New 12-Month High at $62.67” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/16/enanta-pharmaceuticals-enta-hits-new-12-month-high-at-62-67.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.